Last update 29 Aug 2025
Chancellor, Masters & Scholars of The University of Oxford

Chancellor, Masters & Scholars of The University of Oxford

Subsidiary Company|2011|United Kingdom|
10,000-50,000
|
isaric.org

Overview

Tags

Neoplasms
Small molecule drug
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Top 5 Drug TypeCount
Small molecule drug1
Monoclonal antibody1
Top 5 TargetCount
BPTF(bromodomain PHD finger transcription factor)1
HLA-E(major histocompatibility complex, class I, E)1

Related

2
Drugs associated with Chancellor, Masters & Scholars of The University of Oxford
WO2023023663
Patent Mining
Target
HLA-E
Mechanism-
Active Org.
Duke UniversityDuke University [+1]
Originator Org.
Duke UniversityDuke University [+1]
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
WO2025075967
Patent Mining
Target
BPTF
Mechanism-
Active Org.
Chancellor, Masters & Scholars of The University of OxfordChancellor, Masters & Scholars of The University of Oxford [+1]
Originator Org.
Chancellor, Masters & Scholars of The University of OxfordChancellor, Masters & Scholars of The University of Oxford [+1]
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Chancellor, Masters & Scholars of The University of Oxford
NCT05047822
/ CompletedNot Applicable
Real-world Effectiveness of the Oxford/AstraZeneca COVID-19 Vaccine in England. An Observational Retrospective Cohort Study Using Secondary Databases to Establish Effectiveness of the Oxford/AstraZeneca COVID-19 Vaccine in England.
100 Clinical Results associated with Chancellor, Masters & Scholars of The University of Oxford
Login to view more data
0 Patents (Medical) associated with Chancellor, Masters & Scholars of The University of Oxford
Login to view more data
100 Deals associated with Chancellor, Masters & Scholars of The University of Oxford
Login to view more data
100 Translational Medicine associated with Chancellor, Masters & Scholars of The University of Oxford
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
WO2023023663
 ( HLA-E )Patent Mining		Neoplasms
More
Discovery
WO2025075967
 ( BPTF )Patent Mining		Neoplasms
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free